Higher dose needed: Demand and revenue have fallen despite growing spending on pet care
Veterinary pharmaceutical and medicinal product manufacturers are facing mixed operating conditions. Declines in dairy cattle, sheep and deer numbers are reducing demand for veterinary pharmaceuticals. Meanwhile, rising beef cattle herd sizes and increased spending on pet health care are driving sales. Concerns over antibiotic resistance are disrupting an important source of income for veterinary pharmaceutical manufacturers. Pandemic-related supply chain issues are also causing foreign demand to fluctuate, with manufacturers that have operations overseas opting to produce there instead of exporting. Overall, revenue is expected to fall at an annualised 0.6% over the five years through 2022-23 - including a current-year increase by 0.4% - to $516.5 million, while profit has slipped to an estimated 6.6%.
Industry operators primarily manufacture drugs, medicines, medicinal chemicals, vaccines, serums and other pharmaceutical products for veterinary use.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry's key players and their market shares.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Schering-Plough Animal Health Limited
- Zoetis New Zealand Limited
- Virbac New Zealand Limited
Methodology
LOADING...
